New pill combo aims to tackle tough myeloma
NCT ID NCT05530421
First seen Feb 27, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This phase 2 trial is testing whether a combination of three oral drugs—selinexor, venetoclax, and dexamethasone—can shrink tumors in people with a specific genetic subtype of multiple myeloma (t(11;14)) that has returned or stopped responding to treatment. About 33 participants will receive the drugs daily. The main goal is to see how many patients achieve a partial or complete response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Miami, Lennar Foundation Medical Center
RECRUITINGCoral Gables, Florida, 33146, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Miami, Sylvester Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
University of Miami, Sylvester Comprehensive Cancer Center at Deerfield Beach
RECRUITINGDeerfield Beach, Florida, 33442, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selinexor, venetoclax, and dexamethasone (three drugs taken as pills)
What this could lead to
If this works, it could offer a new treatment option for people with a hard-to-treat form of multiple myeloma that has come back after other therapies.
What could go wrong
This is a small, early-phase study (33 people) with no control group, so results may not apply broadly. The drug combination can cause side effects like nausea, fatigue, and low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.